LIFE – Lifecare ASA uplisting to Euronext Oslo Børs is approved

Bergen, Norway, 21 October 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce that the company will transfer to Euronext Oslo Børs tomorrow 22 October 2024.

Reference is made to stock exchange announcement 27 September 2024 where it was announced that Oslo Børs has resolved to admit the shares of Lifecare ASA to trading on Oslo Børs. Today the commission at Euronext Oslo Børs approved Lifecare’s transfer from Euronext Growth to Euronext Oslo Børs.

– This is an important milestone for Lifecare to take the step to the regulated market Euronext Oslo Børs. On behalf of the entire organization, I am very proud that Oslo Børs’ listing committee has assessed and concluded that Lifecare meets the conditions for admission to the main list. We have a proven the technology, we have focused on setting up production and we are now approaching our first product. Lifecare is now ready for the main list on Euronext Oslo Børs, says CEO Joacim Holter at Lifecare ASA.

Tuesday morning, 22 September 2024, Lifecare will ring the bell to mark the opening of the markets at Oslo Børs.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM“) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR“) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

LIFE – Lifecare ASA uplisting to Euronext Oslo Børs is approved